This review presents recent findings with regard to the cellular and molecular mechanisms of neuronal apoptosis induced by cerebral ischemia/hypoxia. The protection of neuronal death by hypoxia-induced proteins in the endoplasmic reticulum (ER) is also reviewed. The excess amount of nitric oxide (NO) generated by inducible NO synthase (iNOS) up-regulated in response to ischemic stress causes neuronal apoptosis through following processes; 1) reduction in mitochondrial membrane potential, 2) release of cytochrome c from mitochondria, and 3) activation of caspase-9 and -3, although low concentrations of NO protect against neuronal death. In contrast, hypoxia induces expression of several proteins such as protein disulfide isomerase (PDI), ubiquilin and HRD1 in the endoplasmic reticulum (ER). PDI and ubiquilin are involved in the protection against neuronal apoptosis probably by interacting with each other and enhancing the effects of PDI as a molecular chaperon. HRD1 is also up-regulated by hypoxia in the ER and induces protection against hypoxia-induced neuronal apoptosis by activating the protein degradation system. The present review hopefully gives pertinent suggestions for further studies on the development of novel prophylactic/therapeutics for neuronal apoptosis-related diseases.
Neuronal death seems to play crucial roles in the cognitive deficits of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and cerebral ischemic-induced dementia. Cerebral ischemia causes the expression of an inducible type of nitric oxide (NO) synthase (iNOS) in glial cells as well as the activation of a type of neuronal NOS (nNOS) in neurons, resulting in neuronal apoptosis due to excessive amounts of NO 1) (Fig. 1 ). Reactive peroxynitrite generated by the reaction of NO with superoxide could be involved in NO-induced neuronal death.
2) Cellular and molecular pharmacological studies using cultured neuroblatoma SH-SY5Y cells 3) have suggested that NO causes apoptosis through the following process: 1) the decrease in mitochondrial membrane potential, 2) release of cytochrome c from the mitochondria, 3) caspase activation, 4) degradation of caspase-acticated DNase (CAD) 4, 5) inhibitors and 5) CAD activation (Fig. 1) . As mentioned above, one of the primary targets of NO action seems to be the mitochondria, since NO leads to the release of cytochrome c from the mitochondria, and the subsequent formation of a complex of cytochrome c, apoptotic protease activity factor-1 (Apaf-1) and caspase-9, which initiates the cleavage and activation of caspase-3. It is of interest that cyclosporin A (CsA, an inhibitor of cyclophilin D) and bongkrekic acid {BA, an adenine neulotides translocator (ANT) in mitochondrial permeability transition pore complex (PTPC)}, can recover from the loss of mitochondrial membrane potential in response to NO (Fig. 2) . Furthermore the findings that 1) CsA is able to decrease NOinduced cytochrome c release from the mitochondria and 2) apoptotic cell death is reduced by BA treatment, suggesting Possible involvement of glial iNOS and neuronal nNOS. Glial iNOS attacks neurons and induces apoptosis by the following process: 1) reduction in membrane potential of the mitochondria, 2) release of cytochrome c from the mitochondria, 3) activation of caspase-9, -3 and -7, etc., 4) degradation of ICAD by caspase-3/-7, 5) translocation of CAD into nucleus and 6) fragmentation of DNA. NO also seems to cause tyrosine nitration of caspases, leading to an inhibition of their activity.
that PTPC complexes are closely involved in cytochrome c release as well as in the maintenance of membrane potential in the mitochondria.
3)
Glyceraldehydre-3-phosphate dehydrogenase (GAPDH, Dglyceraldehydre-3-pbosphate: NAD ϩ oxide reductase) is a key enzyme in the glycolytic conversion of glucose to pyruvic acid and represents an important pathway for carbohydrate metabolism in most organisms. 6 ) GAPDH undergoes endogenous ADP-ribosylation in response to NO 7, 8) and NO donors inhibit GAPDH activity.
7) It is also suggested that the mode of NO action is as follows: 1) NO-induced S-nitrosylation or an NO-stimulated reaction to NAD 9) or 2) the covalent binding of NAD through an NO-dependent thiol intermediate. 10) Koningic acid (heptelidic acid) has been known as a specific modifier of GAPDH by binding to the sulfhydryl residue at the active site of the enzyme.
11) The cysteine residue corresponding to Cys 149 in purified muscle GAPDH, which is an essential residue for the enzyme activity, is the site modified by koningic acid. 7, 8) Since koningic acid as well as sodium nitroprusside (SNP), a NO donor, induced nucleosomal DNA fragmentation and inhibition of GAPDH activity in NG108-15 cells, we have suggested that NO-induced neuronal death is due to NO-mediated ADP-ribosylation and inhibition of GAPDH activity 7) (Fig. 1) . In contrast, it should be noted that GAPDH displays a number of diverse functions unrelated to its glycolytic activity; i.e., membrane fusion, microtubule bundling, phosphotransferase activity, nuclear RNA transport, DNA replication and DNA repair. 12) In particular, nuclear translocation of overexpressed GAPDH seems to be one of the primary events initiating the apoptotic death pathway.
13) It would be of interest to further investigate the relationship between NO-induced neuronal death and GAPDH.
We also found the following inhibitory effects of NO on apoptosis at lower concentrations: 1) 1-chloro-2,4-dinitrobenzene (DNCB), an inhibitor of thioredoxin reductase, induces cell death where is inhibited by ZVAD-fmk, an inhibitor of caspase-3, in both PC12 and primarily cultured rat glial cells and 2) DNCB-induced cell death is inhibited by a relatively low concentration of the NO donor, NOC-18.
14) It is likely that NO can cause nitrosylation/denitrosylation in cysteine/tyrosine residues in caspase-3, followed by inhibition/activation and result in the regulation of cell death.
9) PROTECTION FROM NEURONAL DEATH BY PROTEIN DISULFIDE ISOMERASE, UBIQUILIN AND HRD1 UP-REGULATED BY HYPOXIA
In contrast to the fragility of neurons to hypoxic stress, glial cells show tolerance to such stress. To elucidate the molecular basis of glial tolerance to hypoxia, experimental analysis of molecules up-regulated in glial cells in response to hypoxia has been performed. We isolated and identified protein disulfide inomerase (PDI) in primarily cultured rat astroglial cells. The up-regulation of PDI expression is not only observed in rat glial cells in vitro but also in the rat forebrain after transient ischemia in vivo.
15) The overexpression of this gene results in attenuation of the loss of cell viability induced by hypoxia in human neuroblastoma SK-N-MC cells and a reduction in the member of DNA-fragmented cells in the CA1 area of the hippocampus of rats subjected to cerebral ischemia. From these findings, it is suggested that 1) PDI up-regulated in the ischemic brain could be partially involved in the acquisition of tolerance to ischemic stress and 2) PDI possesses neuroprotective effects against hypoxia. It should be noted that PDI is localized in the endoplasmic reticulum (ER) and up-regulated in response to ER stress such as hypoxia/hypoglycemia or functional disturbance of ER treated by tunicamysin (an inhibitor of N-glycosylation) and thapsigargin (an inhibitor of Ca 2ϩ -ATPase). In addition, other proteins such as calnexin and calreticulin localizing in the ER are also up-regulated in response to hypoxia.
Ubiquilin is identified as a protein that interacts with PDI using the yeast two-hybrid system. We observed that ubiquilin together with PDI are localized in the ER and upregulated in response to hypoxia. 16) Coexpression of ubiquilin-and PDI-genes in neurobastoma SH-N-MC cells results in greater tolerance to hypoxia-induced apoptosis than does the overexpression of PDI or ubiquilin gene alone in the cells, suggesting that PDI and ubiquilin up-regulated in the ER in response to hypoxia cooperatively interact to increase tolerance to hypoxia in glial cells (Fig. 3) . It has been shown that the exposure of cells to various stresses interfering with the functions of the ER leads to the accumulation of unfolded proteins in the ER. Under these conditions, the expression of a variety of genes involved in preventing the ac- cumulation of the unfolded proteins is induced. The above mentioned PDI, GRP78 and ubiquilin are all examples. We recently identified human HRD1 and SEL1, homologues of yeast Hrd1p and Hrd3p, respectively, which have been shown to locate in the ER of yeast. [17] [18] [19] Interestingly, both HRD1 and SEL1 are up-regulated by hypoxic stress and the overexpression of HRD1 results in tolerance to ER stress-induced cell death. Since we found that HRD1 possesses ubiquitin ligase (E 3 ) 18) activity, the protective effects of HRD1 on neuronal death are presumably due to the enhancement of the ubiquitin-proteasomal degradation system of unfolded proteins (Fig. 3) . Other proteins expressed in the ER seem to be involved in the prevention of the accumulation of the unusual proteins in the ER. To develop useful medicines for neuronal death-related diseases, it is important to isolate and identify the functional proteins playing roles in the ER-associated protein degradation and to elucidate the mechanism of the involvement of the proteins in neuronal death.
CONCLUSION
Investigation of the molecular mechanism of neuro-glial interaction is important for the development of novel prophylactics and therapeutics against neuronal death in neurodegenerative diseases. In particular, the isolation and identification of novel molecules influencing neuronal survival/death is important. This review focused on, NO, PDI, ubiquilin and HRD1 and discussed the mechanisms of neuronal death and protections, and the author believes that the approaches and findings presented here in provide a clue to the development of novel prophylactics/therapeutics against nenronal death in neurodegenerative diseases.
